Semiquantitative RT-PCR method coupled to capillary electrophoresis to study 5alpha-reductase mRNA isozymes in rat ventral prostate in different androgen status.

作者: Jesus M. Torres , José A. Gómez‐Capilla , Estrella Ruiz , Esperanza Ortega

DOI: 10.1023/A:1024902419502

关键词: Internal medicineTestosteroneAndrogenIsozymeProstatic DiseasesPCA3BiologyEndocrinologyCancer researchDihydrotestosteroneProstateProstate cancer

摘要: The development and growth of the prostate gland depends on androgen stimulation. Dihydrotestosterone (DHT) is primary responsible for also pathogenesis benign prostatic hyperplasia (BPH). incidence cancer (PCa) hypertrophy (BPH) continues to rise in Western world. DHT synthesized from circulating testosterone (T) through action 5α-Reductase (5α-R) (EC 1.3.99.5), which occurs as two isozymes, type 1 2. Type-1 5α-R widely distributed body, type-2 confined androgen-dependent structures. Both types are expressed prostate: isozyme implicated BPH PCa; type-1 increased some adenocarcinomas. In recent years, various inhibitors or both have been used diseases. this work we present measurements mRNA levels steroid isozymes ventral rats different status. We a novel method that combines high specificity semiquantitive PCR with sensitivity laser-induced capillary electrophoresis (LIF-CE). demonstrated T control expression 5α-R2 rat prostrate. This approach could be great value study diseases humans would allow at transcriptional level effects drugs inhibit either these isozymes.

参考文章(26)
E P Jenkins, S Andersson, J Imperato-McGinley, J D Wilson, D W Russell, Genetic and pharmacological evidence for more than one human steroid 5α-reductase Journal of Clinical Investigation. ,vol. 89, pp. 293- 300 ,(1992) , 10.1172/JCI115574
Peter Boyle, Chris Robertson, Franklin Lowe, Claus Roehrborn, Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia Urology. ,vol. 55, pp. 533- 539 ,(2000) , 10.1016/S0090-4295(99)00593-2
ATSUKO SHIBATA, THOMAS A. STAMEY, JOHN E. McNEAL, IONA CHENG, DONNA M. PEEHL, GENETIC POLYMORPHISMS IN THE ANDROGEN RECEPTOR AND TYPE II 5α-REDUCTASE GENES IN PROSTATE ENLARGEMENT The Journal of Urology. ,vol. 166, pp. 1560- 1564 ,(2001) , 10.1016/S0022-5347(05)65830-2
H. Wong, W.D. Anderson, T. Cheng, K.T. Riabowol, Monitoring mRNA Expression by Polymerase Chain Reaction: The "Primer-Dropping" Method Analytical Biochemistry. ,vol. 223, pp. 251- 258 ,(1994) , 10.1006/ABIO.1994.1581
William D. Steers, 5α-reductase activity in the prostate Urology. ,vol. 58, pp. 17- 24 ,(2001) , 10.1016/S0090-4295(01)01299-7
D M Berman, H Tian, D W Russell, Expression and regulation of steroid 5α-reductase in the urogenital tract of the fetal rat Molecular Endocrinology. ,vol. 9, pp. 1561- 1570 ,(1995) , 10.1210/MEND.9.11.8584033
Alain G. Latil, Rahm�ne Azzouzi, G�raldine S. Cancel, Emmanuelle C. Guillaume, B�atrix Cochan-Priollet, Philippe L. Berthon, Olivier Cussenot, Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer. ,vol. 92, pp. 1130- 1137 ,(2001) , 10.1002/1097-0142(20010901)92:5<1130::AID-CNCR1430>3.0.CO;2-B
S. Andersson, D. W. Russell, Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 87, pp. 3640- 3644 ,(1990) , 10.1073/PNAS.87.10.3640
C M Smith, S A Ballard, N Worman, R Buettner, J R Masters, 5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. The Journal of Clinical Endocrinology and Metabolism. ,vol. 81, pp. 1361- 1366 ,(1996) , 10.1210/JCEM.81.4.8636334